Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.

I G Schmidt-Wolf(Stanford University), I L Weissman(Stanford University), Hans‐Peter Kiem(Fred Hutch Cancer Center), RS Negrin(Stanford University), KG Blume(Stanford University)

The Journal of Experimental Medicine

July 1, 1991

10.1084/jem.174.1.139

Cited by 623

Related Papers

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

|Blood|2001|1.4k

Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy

|Blood|1993|284

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies

|Blood|2020|217

Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy

|Blood|1996|209

Stable Mixed Hematopoietic Chimerism in Dog Leukocyte Antigen–Identical Littermate Dogs Given Lymph Node Irradiation Before and Pharmacologic Immunosuppression After Marrow Transplantation

|Blood|1999|150